Very proud to announce the closing of the new funding round of our portfolio company Pan Cancer T! Stay tuned for their updates!
Pan Cancer T secures €4.25M seed extension round We are delighted to announce the successful closing of Pan Cancer T’s €4.25 million seed extension round, which will accelerate development of our next-generation T cell therapies. See press release: https://t.ly/CjFGq This financing round will enable us to advance our lead TCR-T cell product, PCT1:CO-STIM, to the clinic for the treatment of triple negative breast cancer, and support progression of earlier-stage pipeline projects. It also provides a firm foundation to secure a Series A round within the coming year and seek business development partnerships with Biotech and Pharma collaborators to further develop our assets (including our TCR:CO-STIM platform that is applicable to other TCRs and tumour indications). We would like to welcome our new investor, InnovationQuarter, and thank our existing investors, Van Herk Ventures (Van Herk Groep), Thuja Capital, Swanbridge Capital and Erasmus MC O&O Holdings, for their continued support.